Company News

  • 17 May 2019

    Roche reports positive Phase I/II data for entrectinib

    Roche has reported that its investigational personalised medicine entrectinib shrank tumours in the Phase I/II STARTRK-NG clinical trial involving children and adolescents with recurrent or refractory solid tumours.

Go Top